Immutep Ltd · ASX:IMM
Immutep — Technical Presentation (July 2024)
15 slides from Immutep's technical presentation, Jul 11, 2024
Slide 1: Global Webcast Slides for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B)
Global Webcast Slides for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B) Presented at ESMO Virtual Plenary session at 18:30-19:30 Central European Time (CEST), July 11, 2024 Global Webcast Presentation – July 12th, at 9am AEST (July 11th, at 7pm ET) Registration: Webca
Slide 2: Forward-Looking Statements
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati
Slide 3: Complementary Effect of Efti with KEYTRUDA
Complementary Effect of Efti with KEYTRUDA • Eftilagimod alfa: a soluble LAG-3 protein and MHC Class II agonist that leads to an enhanced immune response by activating antigen presenting cells (APCs), leading to the activation/proliferation of CD8+ T cells and other anti-cancer immune cells/chemokin
Slide 4: Treatment Landscape for CPS <1 Patients
Treatment Landscape for CPS <1 Patients PD-L1 expression: • PD-L1 expression as measured by Combined Proportion Score (CPS) is an FDA- Recurrent, unresectable, or metastatic disease not amenable to curative RT or surgery and CPS <1 approved predictive biomarker in 1L HNSCC for anti-PD-1 therapy Limi
Slide 5: TACTI-003 / KEYNOTE-PNC-34 Study Design
TACTI-003 / KEYNOTE-PNC-34 Study Design TACTI-003: a multicentre, randomised open-label Phase IIb trial with 2 cohorts. Today’s focus: Cohort B*: CPS <1, patients treated with efti and KEYTRUDA (pembrolizumab) Treatment: eftilagimod 30 mg s.c. Q2W + KEYTRUDA IV 400 mg Q6W for max. 2 years. Radiologi
Slide 6: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Baseline parameters N=311 Median age, years (range) 64 (23-83) • 33 patients were recruited at 14 sites across 6 countries between Apr 2022-Oct 2023, of which 31 patients were Female / Male, % 25.8 / 74.2 evaluable ECOG PS 0 / 1, % 32.3 / 67.7 • CPS us
Slide 7: Continued Strong Safety Profile
Continued Strong Safety Profile Summary of TEARs (Safety population) Most frequent TEAEs (Safety population) Safety parameters, n (%) N=33 Preferred term (incidence ≥15%), n (%) N=33 Any TEARs 24 (72.7) Fatigue 7 (21.2) Any TEARs with Grade ≥3 5 (15.2) Weight decreased 6 (18.2) Any TEARs Leading to
Slide 8: Tumour Response Rate Among Highest Recorded in CPS <1
Tumour Response Rate Among Highest Recorded in CPS <1 RECIST 1.1 iRECIST Best objective response1, n (%) Key Takeaways: N=31 N=31 Complete response 3 (9.7) 3 (9.7) • ORR of 35.5% and DCR of 58.1%, according to RECIST 1.1 Partial response 8 (25.8) 9 (29.0) • The 35.5% ORR is among the highest recorde
Slide 9: Tumour Shrinkage in 60% of Patients
Tumour Shrinkage in 60% of Patients Change in Tumour Burden • ~60% of patients experienced tumour shrinkage • Despite deep responses in target lesions, two patients not counted as responders: ➢ One patient (*) with pseudoprogression later had a confirmed partial response (PR) according to iRECIST ye
Slide 10: Confirmed Partial Response per iRECIST after Pseudoprogression
Confirmed Partial Response per iRECIST after Pseudoprogression 55-year-old male; HNSCC of oropharyngeal origin (HPV negative) • Patient had two malignant lymph nodes (LN) as target lesions and one LN non-target lesion (NTL) at baseline • The target lesions started to shrink at week 9, yet the appear
Slide 11: Excellent Duration of Treatment
Excellent Duration of Treatment Tumour response dynamics over time* Tumour response dynamics (RESPONDERS only) • Durability of treatment / responses tracks very well • >50% patients remain on treatment 6+ months • >90% of responders remain on treatment 6+ months Data cut-off date: March 11, 2024. Pa
Slide 12: Benchmarking: Exceptional Results for a Chemo-Free Regimen
Benchmarking: Exceptional Results for a Chemo-Free Regimen Objective Complete Response Rate Responses Key takeaways, Cohort B (CPS <1) ✓ ORR of 35.5% and DCR of 58.1% are exceptional for a chemo-free regimen in this patient population ✓ Compares favorably to historical results from KEYTRUDA monother
Slide 13: Limited Competition in a Valuable Market
Limited Competition in a Valuable Market Limited competition in CPS <1 • 35.5% ORR among the highest reported for chemotherapy-free regimen in CPS <1 • Durability tracking well: >50% patients remain on treatment 6+ months and >90% of responders remain on treatment 6+ months • Most IO combinations wi
Slide 14: Outlook
Outlook Milestones & Catalysts Ahead • Non-Small Cell Lung Cancer – TACTI-004 preparations for study start with FPI in late 2024 / early 2025 • Non-Small Cell Lung Cancer – Update from triple combo INSIGHT-003 trial • Head and Neck Squamous Cell Carcinoma – Additional data will be presented in H2 CY
Slide 15: Thank you
: @ Immutep Thank you